(Q52364971)

30 April 2018

title

Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study. (English)

1 reference

30 April 2018

0 references

P S Hansen

1

1 reference

30 April 2018

H Meinertz

2

1 reference

30 April 2018

L U Gerdes

3

1 reference

30 April 2018

I C Klausen

4

1 reference

30 April 2018

O Faergeman

5

1 reference

30 April 2018

publication date

1 December 1994

1 reference

30 April 2018

Journal of Molecular Medicine

published in

1 reference

30 April 2018

volume

72

1 reference

30 April 2018

page(s)

1065-1070

1 reference

30 April 2018

issue

12

1 reference

30 April 2018

https://scigraph.springernature.com/pub.10.1007/bf00577757

exact match

0 references

cites work

Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

1 reference

12 December 2020

Effects of fluvastatin (XU 62-320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans

1 reference

12 December 2020

Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.

1 reference

12 December 2020

Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration

1 reference

12 December 2020

A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. The Lovastatin Pravastatin Study Group

1 reference

12 December 2020

The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia

1 reference

12 December 2020

The discovery and development of HMG-CoA reductase inhibitors

1 reference

12 December 2020

Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma

1 reference

12 December 2020

Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants

1 reference

12 December 2020

Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin

1 reference

12 December 2020

Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women

1 reference

12 December 2020

Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100

1 reference

12 December 2020

Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil

1 reference

12 December 2020

Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia

1 reference

12 December 2020

Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI

1 reference

12 December 2020

Differences in apolipoprotein (a) polymorphism in west Greenland Eskimos and Caucasian Danes

1 reference

12 December 2020

Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor.

1 reference

12 December 2020

Long-term effect of lovastatin alone and in combination with cholestyramine on lipoprotein (a) level in familial hypercholesterolemic subjects

1 reference

12 December 2020

The two-period cross-over clinical trial

1 reference

12 December 2020

Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100

1 reference

12 December 2020

Familial defective apolipoprotein B100: clinical characteristics of 54 cases

1 reference

12 December 2020

Influence of lovastatin on concentrations and composition of lipoprotein subfractions

1 reference

12 December 2020

Detection of the apoB-3500 mutation (glutamine for arginine) by gene amplification and cleavage with MspI

1 reference

12 December 2020

The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism

1 reference

12 December 2020

Characteristics of 46 heterozygous carriers and 57 unaffected relatives in five Danish families with familial defective apolipoprotein B-100.

1 reference

12 December 2020

Hypocholesterolemic effects of cholestyramine and colestipol in patients with familial defective apolipoprotein B-100

1 reference

12 December 2020

Hypocholesterolaemic effects of lovastatin in familial defective apolipoprotein B-100

1 reference

12 December 2020

Familial defective apolipoprotein B-100. Comparison with familial hypercholesterolemia in 18 cases detected in Munich

1 reference

12 December 2020

Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease

1 reference

12 December 2020

Response to cholesterol-lowering drugs in familial defective apolipoprotein B-100

1 reference

12 December 2020

Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes

1 reference

12 December 2020

Drug treatment of dyslipoproteinemia

1 reference

12 December 2020

Hypolipidemic therapy modulates expression of apolipoprotein B epitopes on low density lipoproteins. Studies in mild to moderate hypertriglyceridemic patients.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00577757

1 reference

30 April 2018

PubMed ID

7711417

1 reference

30 April 2018